A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
about
Open drug discovery for the Zika virusPhosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic StrategiesAddressing Therapeutic Options for Ebola Virus Infection in Current and Future OutbreaksChloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivityRepurposed therapeutic agents targeting the Ebola virus: a protocol for a systematic reviewChloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell ModelsClomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic ImplicationsMinimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig ModelVirtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infectionInsights from clinical research completed during the west Africa Ebola virus disease epidemic.Ebola virus: A gap in drug design and discovery - experimental and computational perspective.The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infectionA screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target.Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig modelScreening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Small molecules with antiviral activity against the Ebola virusEbola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.In silico analysis suggests interaction between Ebola virus and the extracellular matrixAntiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.Lack of protection against ebola virus from chloroquine in mice and hamstersImproving attrition rates in Ebola virus drug discovery.Screen of FDA-approved drug library identifies maprotiline, an antibiofilm and antivirulence compound with QseC sensor-kinase dependent activity in Francisella novicida.In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease.Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection.High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication.Machine learning models identify molecules active against the Ebola virus in vitroFrancisella tularensis Susceptibility to Antibiotics: A Comprehensive Review of the Data Obtained In vitro and in Animal Models.Imino sugar glucosidase inhibitors as broadly active anti-filovirus agentsA host-oriented inhibitor of Junin Argentine hemorrhagic fever virus egress.Reverse genetics systems as tools for the development of novel therapies against filoviruses.Potential and emerging treatment options for Ebola virus disease.Development of experimental and early investigational drugs for the treatment of Ebola virus infections.Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.Development of Small-Molecule Antivirals for Ebola.Novel drug discovery approaches for treating arenavirus infections.Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis.
P2860
Q22676298-C42A16B1-138D-40F9-8920-C50AE850C4EBQ24701734-A099B05A-5C1E-465F-AEFF-55AF86190E8EQ26801423-D2E7A3B5-231A-4372-BB28-127597945A1AQ28066142-DE1580DB-B95A-4894-875C-2402E31D45DAQ28087046-48D2578F-6AC7-4FE3-B831-D26767DF99AAQ28353981-040C61BC-BA06-4650-81E1-6E4C80C7FC0AQ28387522-31BD980D-D895-4804-93AA-C28320BE5C2DQ28553683-2F27A26E-8101-4102-878A-4DA3480790AAQ28649882-500A19BF-FEA8-43E1-AA7F-B379C9CC4FBCQ30234590-C66EB57E-0364-4622-BD3F-C89712763B8DQ30243938-103ADF30-8788-4FD1-BBFB-1B14F2BF7BC2Q30252649-BE1BC5C9-323C-49E3-9CFD-226662D32AE0Q30279239-020FD6A7-6A2B-452C-AA47-88F59209DA1CQ30376138-FABCD5B8-58F1-4420-B888-F6D0D308F85AQ30419612-CED73291-04AE-4105-B4AD-A9B44C354FEAQ33617999-5A2F612F-FEE8-4E9A-8CE8-9FABF040312AQ34058365-12AE8FD8-F83E-4373-9176-405E297E18E7Q34463780-BB420915-9F06-434B-8E51-D6EAAC9A73C2Q34464403-0D34B06C-1EE4-4B43-8858-0CFDCC8C79AAQ34464824-44DBCEAD-13EB-437F-809E-1644770EC7A4Q35050840-FFFA6C8B-287D-4606-A5EB-31E1DA9A37D3Q35099536-6E4676C8-7029-4FB6-8BDC-01F96C8DCAB3Q35605579-6BFC83A1-2FA2-4B13-BFF9-8BDC0755A34FQ35673457-E183CD31-0CBB-45B0-91DA-E3DE4EAD4463Q35678774-0954A6C1-4081-473E-992C-7B7BAA18B62AQ35686324-A2714816-2AE8-4825-9333-5D12909A759DQ35689217-A5063814-AEA0-419C-9AC7-7D97EDF702B3Q35718193-095BA734-7EBD-41FB-B2EA-2ED3C297187FQ35748556-E03C438D-6E48-4BC7-8F71-7F26195059B3Q35911643-9FC16F9F-4696-4558-BDBA-50B3DC19D094Q36356257-98F77E0E-070A-4BA1-A83C-C93A75894D99Q37584342-A266651C-E545-4693-B156-0918D0DB72D2Q37714018-6DE0C450-F047-40AD-8FB4-85D26871F682Q38244444-B108088A-E186-4301-A3CA-F6CCEEF33E91Q38270149-494C03F1-2536-4ED4-A589-DE74ACDB6688Q38524949-7B7022FE-63D9-459A-AD80-5C8F6F6B3038Q38530430-B3C8325B-919C-4B06-9D81-A2D372573C71Q38546746-B74731EB-949C-4DB9-918B-9288108604E9Q38735837-B71926A8-756C-4B97-BF39-A03C08D66A61Q38820203-DF7A9396-71AC-4116-B84D-CE6BFF7BB36B
P2860
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@ast
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@en
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@en-gb
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@nl
type
label
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@ast
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@en
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@en-gb
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@nl
altLabel
A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
@en
prefLabel
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@ast
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@en
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@en-gb
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@nl
P2093
P2860
P50
P3181
P1433
P1476
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents
@en
P2093
Amy C Shurtleff
Andrey A Kolokoltsov
Carol E Green
Holli Hutcheson Dilks
Ian D Manger
Jay B Wells
Jean L Patterson
Lalitha V Iyer
Lynne Gilfillan
Mary J Tanga
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0060579
P407
P577
2013-01-01T00:00:00Z